"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
| Descriptor ID |
D009465
|
| MeSH Number(s) |
D27.505.696.663.700
|
| Concept/Terms |
Neuromuscular Effect- Neuromuscular Effect
- Effect, Neuromuscular
- Neuromuscular Effects
- Effects, Neuromuscular
|
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".
This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 2 | 5 |
| 2004 | 5 | 1 | 6 |
| 2005 | 3 | 1 | 4 |
| 2006 | 3 | 2 | 5 |
| 2008 | 3 | 0 | 3 |
| 2009 | 4 | 0 | 4 |
| 2010 | 5 | 2 | 7 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 1 | 5 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 1 | 4 |
| 2019 | 4 | 1 | 5 |
| 2020 | 7 | 0 | 7 |
| 2021 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
| 2024 | 2 | 5 | 7 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.
-
Zorowitz RD, Jacinto J, Ashford S, Beneteau M, Maisonobe P, Hannes C, Esquenazi A. Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice. J Rehabil Med. 2025 Feb 07; 57:jrm42605.
-
Esquenazi A, Zorowitz RD, Ashford S, Beneteau M, Maisonobe P, Hannes C, Jacinto J. Longitudinal Goal Attainment With Repeat Injections of AbobotulinumtoxinA in Adults With Lower Limb Spasticity: Results From a Prospective Observational Study. Arch Phys Med Rehabil. 2025 06; 106(6):894-901.
-
Gollomp SM, Khalifian S, Gokhale S. Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics. Dermatol Surg. 2024 09 01; 50(9S):S35-S37.
-
Heckert K, Biering-S?rensen B, B?umer T, Khan O, Pagan F, Paulin M, Stitik T, Verduzco-Gutierrez M, Reebye R. Delphi Analysis: Optimizing Anatomy Teaching and Ultrasound Training for Botulinum Neurotoxin Type A Injection in Spasticity and Dystonia. Toxins (Basel). 2024 08 21; 16(8).
-
Pozo-Rosich P, Alpuente A, Silberstein SD, Burstein R. Insights from 25?years of onabotulinumtoxinA in migraine - mechanisms and management. Nat Rev Neurol. 2024 09; 20(9):555-568.
-
Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache. 2024 Jul-Aug; 64(7):838-848.
-
Bavikatte G, Francisco GE, Jost WH, Baricich A, Duarte E, Tang SFT, Schwartz M, Nelson M, Musacchio T, Esquenazi A. Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study. PM R. 2024 11; 16(11):1175-1189.
-
Bavikatte G, Esquenazi A, Dimyan MA, Dashtipour K, Feng W, Mayadev A, Fanning K, Musacchio T, Zuzek A, Francisco GE. Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study. Am J Phys Med Rehabil. 2024 07 01; 103(7):580-587.
-
Esquenazi A, Zorowitz RD, Ashford S, Maisonobe P, Page S, Jacinto J. Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study. J Rehabil Med. 2023 Oct 05; 55:jrm4257.
-
Esquenazi A, Jost WH, Turkel CC, Wein T, Dimitrova R. Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32376.